First patient dosed in IST of CDK inhibitor seliciclib in Cushing's disease
Cyclacel announced the first patient has been dosed in an investigator sponsored trial of the Company's oral cyclin dependent kinase inhibitor seliciclib in Cushing's disease. Clinicians at Cedars-Sinai, Los Angeles, were awarded a grant from NIDDK to evaluate seliciclib. July 02, 2015